Wells Fargo’s Centessa Pharmaceuticals CNTA Stock Holding History

Wells Fargo’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,000	Closed	-$238K	–	7340
2026 Q1	$238K	Buy	6,000 +2,613	+77%	+$66.8K	﹤0.01%	4607
2025 Q4	$84.7K	Buy	3,387 +1,008	+42%	+$25.5K	﹤0.01%	5442
2025 Q3	$57.7K	Buy	2,379 +2,229	+1,486%	+$39.6K	﹤0.01%	5516
2025 Q2	$1.97K	Sell	150 -31,296	-100%	-$397K	﹤0.01%	6217
2025 Q1	$452K	Buy	+31,446	New	+$515K	﹤0.01%	4169
2024 Q3	–	Sell	-520	Closed	-$4.7K	–	6939
2024 Q2	$4.7K	Buy	+520	New	+$4.93K	﹤0.01%	5883

Wells Fargo's CNTA Position: Q2 2026 in Review

Wells Fargo sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 6,000 shares — an estimated $238K sold.

Wells Fargo first reported a position in CNTA in Q2 2024 and held it in 6 quarters. The position peaked at $452K in Q1 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Wells Fargo reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Wells Fargo sold 6,000 Centessa Pharmaceuticals shares in Q2 2026, an estimated $238K.
Wells Fargo first reported a position in Centessa Pharmaceuticals in Q2 2024 and held it in 6 quarters.
Wells Fargo's Centessa Pharmaceuticals position peaked at $452K in Q1 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.